financetom
Business
financetom
/
Business
/
China says it opposes latest US tariff threat after Trump sets Tuesday deadline
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
China says it opposes latest US tariff threat after Trump sets Tuesday deadline
Feb 27, 2025 10:33 PM

BEIJING (Reuters) - Beijing said on Friday it opposed President Donald Trump's latest threat to slap an extra 10% duty on Chinese imports, accusing the U.S. of "shifting the blame" on the flow of fentanyl and promising retaliation to protect its interests.

China's Commerce Ministry said the country has some of the world's strictest anti-drug policies and highlighted the risks new tariffs would bring to global supply chains.

Trump said on Thursday his proposed 25% tariffs on Mexican and Canadian goods will take effect on Tuesday, along with the extra 10% duty on Chinese imports.

The fresh China tariffs, in addition to the 10% tariff levied on Feb 4, coincide with the start of China's annual parliamentary meetings on Wednesday, a set-piece political event where Beijing is expected to unveil its main economic priorities for 2025.

The announcement also leaves Beijing less than a week to publish countermeasures, as the Trump administration shows signs of a hardening stance towards its strategic rival despite backing down on the threat of tariffs of up to 60% when Trump took office.

"China has repeatedly stated that unilateral tariffs violate World Trade Organization rules and undermine the multilateral trading system," a Commerce Ministry spokesperson said in a statement.

"China has one of the strictest and most thoroughly enforced anti-drug policies in the world," it said. "This time, (the U.S.) once again is threatening additional tariffs. Such behaviour is purely 'shifting blame and shirking responsibility,' which is not conducive to solving its own problems."

Analysts say Beijing still hopes to strike a deal with the Trump administration, but with trade talks not materialising yet and the White House ramping up signs it is preparing for a wider economic decoupling from China, the prospect of a rapprochement between the world's top two economies remains unclear.

"There's been a lot of motion, but it's still not clear exactly what the Trump administration's fundamental goal is with respect to China," said Christopher Beddor, deputy China research director at Gavekal Dragonomics.

The Commerce Ministry said it hoped to return to negotiations with the U.S. as soon as possible, warning that failure to do so could trigger retaliation.

"If the U.S. insists on proceeding with this course of action, China will take all necessary countermeasures to safeguard its legitimate rights and interests."

Trump told reporters in the Oval Office on Thursday he decided to add the extra tariffs on China and stick to the Tuesday deadline for Canada and Mexico given what his administration sees as insufficient progress on curbing fentanyl flows into the country.

"There are ongoing discussions with the Chinese, Mexico and Canada," a White House official told Reuters. "We've gotten a good handle on the migration issue, but there are still concerns on the other issue of fentanyl deaths."

China's Public Security Ministry said on Friday it had added seven new precursor chemicals to a domestic control list and 24 new precursor chemicals to an export control list. It said that it had cracked 151 cases of drug-making materials and seized 1,427.4 tons of drug-making materials in the past year, without specifying whether these were related to fentanyl.

(Reporting by Joe Cash and Laurie Chen; Editing by Shri Navaratnam and Lincoln Feast.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Thermo Fisher's Fiscal Q1 Adjusted Earnings Rise While Revenue Falls; Fiscal 2024 Outlook Updated -- Shares Advance Pre-Bell
Thermo Fisher's Fiscal Q1 Adjusted Earnings Rise While Revenue Falls; Fiscal 2024 Outlook Updated -- Shares Advance Pre-Bell
Apr 24, 2024
06:46 AM EDT, 04/24/2024 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) reported fiscal Q1 adjusted earnings Wednesday of $5.11 per diluted share, up from $5.03 a year earlier. Analysts polled by Capital IQ expected $4.71. Revenue for the quarter ended March 30 was $10.34 billion, down from $10.71 billion a year earlier. Analysts surveyed by Capital IQ expected...
Champion Iron Reports Q4 Production and Mining Operation Expenditures
Champion Iron Reports Q4 Production and Mining Operation Expenditures
Apr 24, 2024
06:47 AM EDT, 04/24/2024 (MT Newswires) -- Champion Iron ( CIAFF ) overnight Tuesday reported production results and mining operation expenditures for its financial fourth quarter ended March 31. Detailed operational and audited financial results are to be released prior to the company's conference call and webcast scheduled for May 31. Among highlights from the Q4 update, the company cited...
Liftmaker Otis beats first-quarter profit estimates on high demand for maintenance
Liftmaker Otis beats first-quarter profit estimates on high demand for maintenance
Apr 24, 2024
April 24 (Reuters) - Elevator and escalator maker Otis Worldwide Corp ( OTIS ) beat quarterly profit estimates on Wednesday on higher demand for maintenance and repair services on its elevators. The Farmington Connecticut-based company operates globally through two segments - new equipment which manufactures and installs passenger and freight elevators, escalators and moving walkways, and service segment which offers...
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Apr 24, 2024
April 24 (Reuters) - Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition. The company also said its Alzheimer's drug Leqembi, developed with Japanese partner Eisai ( ESALF ), recorded global sales of about $19 million, nearly tripling from the fourth quarter of 2023. The number...
Copyright 2023-2026 - www.financetom.com All Rights Reserved